+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group



Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group



Lancet 338(8764): 395-398



Vaccines prepared from the polyribosylribitol phosphate (PRP) capsule of Haemophilus influenzae b (Hib) have not consistently shown good efficacy in protecting children aged over 18 months from invasive Hib disease. To evaluate the efficacy of conjugate-PRP vaccines in this age-group, and to compare their effect with that of PRP vaccines, a post-marketing case-control study was conducted among 10,400,000 persons. Between Oct 1, 1988, and Feb 28, 1990, 75 patients with Hib disease and 161 control children between 18 and 60 months of age were enrolled. To minimise potentially confounding socioeconomic variables, controls were selected either from among patients' classmates at their day-care centre or from among family acquaintances. 9 of the 75 patients had received the diphtheria toxoid conjugate Hib vaccine more than 2 weeks before onset of illness. After adjusting for age and household crowding, the efficacy of PRP Hib vaccine was 64% (95% Cl = -20,89) and efficacy of the diphtheria toxoid conjugate Hib vaccine was 74% (95% Cl = 30,90). The study shows that the protective efficacy of this conjugate vaccine is less than ideal and highlights the need for additional post-licensing studies to confirm and expand understanding of the efficacy of these new products.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039989235

Download citation: RISBibTeXText

PMID: 1678080


Related references

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet 338(Aug. 17): 395-398, 1991

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. New England Journal of Medicine 317(12): 717-722, 1987

Protective efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid-conjugate vaccine. American Journal of Diseases of Children 144(3): 292-295, 1990

Studies of safety and immunogenicity of haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in children 7 14 months of age. Pediatric Research 19(4 Part 2): 299A, 1985

Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in vaccinated children who developed Haemophilus disease. Pediatrics 86(4): 617-620, 1990

Response to a booster dose of haemophilus influenzae type b capsular polysaccharide diphtheria toxoid conjugate vaccine in children initially immunized at 3 5 7 or only 7 months. Pediatric Research: 1104, 1985

Response to a booster dose of haemophilus influenzae type b capsular polysaccharide diphtheria toxoid conjugate vaccine prp d in children initially immunized at 9 14 months. Pediatric Research 19(4 Part 2): 300A, 1985

Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. Journal of Pediatrics 106(2): 185-189, 1985

Persistence of antibody and response to booster dose of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infants immunized at 9 to 15 months of age. Journal of Pediatrics 108(6): 882-886, 1986

Immunogenicity of haemophilus influenzae type hib polysaccharide diphtheria toxoid dt conjugate vaccine in children with recurrent respiratory infections. European Journal of Pediatrics 149(5): 374, 1990

Clinical and serologic responses of Saudi children to Haemophilus influenzae type B capsular polysaccharide diphtheria toxoid conjugate vaccine. Annals of Saudi Medicine 13(3): 215-221, 1993

The role of molecular size and protein polysaccharide composition in determining the immunogenicity of an haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in 7 14 month old children. Federation Proceedings 45(3): 381, 1986

Immunogenicity of Haemophilus influenzae type b polysaccharide--diphtheria toxoid conjugate vaccine in adults. Journal of Pediatrics 105(1): 22-27, 1984

Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults. Journal of Infectious Diseases 150(3): 402-406, 1984

Clinical trials of the Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine. Pediatric Infectious Disease Journal 6(8): 804-807, 1987